FDMT - 4D Molecular Therapeutics, Inc. News

B. Riley Securities Initiates Coverage On 4D Molecular Therapeutics with Buy Rating, Announces Price

B. Riley Securities analyst Mayank Mamtani initiates coverage on 4D Molecular Therapeutics (NASDA

schaeffersresearch.com

10 Stock Picks to Celebrate 45 Years of Schaeffer's

Subscribers to Chart of the Week received this commentary on Sunday, July 26.

4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity

4D Molecular Therapeutics, Inc. maintains a Buy rating, driven by advancing 4D-150 gene therapy for

4D Molecular's One-Shot Eye Therapy Delivers Two-Year Win

4D Molecular Therapeutics reports positive 2-year Phase 2b data for 4D-150 in wet AMD, showing up to

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM

Reported Saturday, 4D Molecular Therapeutics' 4D-150 Achieves 78% Overall Treatment Burden Reduction

After a single intravitreal dose of 4D-150, visual acuity and anatomic control was maintained with c

4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population

EMERYVILLE, Calif., July 18, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

EMERYVILLE, Calif., July 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Spec

EMERYVILLE, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics Completes Enrollment For Its 4FRONT-2 Second Phase 3 Clinical Trial Evalua

4FRONT-2 global enrollment completed approximately 4 months ahead of initial projections4FRONT-2 ove

4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD

EMERYVILLE, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT,

zacks.com

Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?

4D Molecular Therapeutics (FDMT) was a big mover last session on higher-than-average trading volume.

EMERYVILLE, Calif., June 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

4D Molecular Therapeutics, Inc. (FDMT) Presents at Goldman Sachs 47th Annual Global Healthcare Confe

4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies Global Healthcare Conference 2026 Trans

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT o

4D Molecular Therapeutics, Inc. (FDMT) Presents at RBC Capital Markets Global Healthcare Conference

marketbeat.com

4D Molecular Therapeutics Touts Rapid Phase 3 Momentum for Retinal Gene Therapy

4D Molecular Therapeutics NASDAQ: FDMT executives said the company is seeing strong clinical trial m

EMERYVILLE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT o

4D Molecular Therapeutics, Inc. (FDMT) Presents at Bank of America Global Healthcare Conference 2026

zacks.com

4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the

4D Molecular Therapeutics Q1 EPS $(1.01) Misses $(0.99) Estimate, Sales $3.047M Miss $5.167M Estimat

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed

4DMT Reports First Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Mile

EMERYVILLE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT o

4DMT to Participate in Upcoming Investor Conferences

EMERYVILLE, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT o

EMERYVILLE, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:FDM

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $35

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo

UPDATE: 4D Molecular Therapeutics Q4 EPS $0.43 Beats $(0.53) Estimate, Sales $85.090M Beat $32.245M

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly earnings of $0.43 per share which beat th

4D Molecular Therapeutics Completes Patient Enrollment In 4FRONT-1 Trial Evaluating 4D-150

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology c

Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings)

BlackBerry, FedEx, Nike And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $26 Price Target

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a

4D Molecular Therapeutics Says Interim Data From 4D-710 Phase 1 AEROW Trial For Cystic Fibrosis Lung

Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $32

RBC Capital analyst Lisa Walter maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperfo

Barclays Maintains Overweight on 4D Molecular Therapeutics, Lowers Price Target to $33

Barclays analyst Gena Wang maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Overweight an

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $26

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a

4D Molecular Therapeutics Q3 EPS $(1.01) Misses $(0.98) Estimate, Sales $90.000K Miss $287.857K Esti

4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(1.01) per share which missed

12 Health Care Stocks Moving In Thursday's Pre-Market Session

4D Molecular Therapeutics Prices $100M Offering Including 8.4M Common Shares At $10.51 Each And 1.1M

4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology co

4DMT's 4D-150 Demonstrates Durable, Multi-Year Benefit Supporting Its Potential As A Backbone Therap

4D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by

Reported Earlier, 4DMT And Otsuka Pharmaceutical Sign $85M Upfront License Deal With Up To $336M In

4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost

Jim Cramer: AppLovin Calls For Prudence, This Health Care Stock Is 'Pure Spec'

Jim Cramer doesn't recommend buying more AppLovin stock. "Let's take a little off the ta

Why Apple Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Why Domino's Pizza Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's

Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday

Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday afte

Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday

Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 56.6% to settle at $19.10 on Friday.

Stocks That Hit 52-Week Lows On Tuesday

On Tuesday, 540 companies set new 52-week lows.

Stocks That Hit 52-Week Lows On Wednesday

During Wednesday's trading, 435 companies set new 52-week lows.